semaglutide
The Rs 12,000 Crore Race for GLP-1 Drugs: Impact on India’s Obesity Crisis
India is witnessing a surge in demand for GLP-1 drugs, potentially transforming obesity treatment while raising regulatory concerns.
Government Increases Oversight on GLP-1 Weight-Loss Drugs Amid Concerns
The Indian government is enhancing oversight of GLP-1 weight-loss drugs amid rising unauthorized sales, prioritizing public safety and regulatory measures.
Indian Drug Manufacturers Launch Affordable Alternatives to Ozempic and Wegovy
Indian drug manufacturers are introducing affordable alternatives to Ozempic and Wegovy, aiming to enhance access to obesity treatment worldwide.
Indian Pharmaceutical Firms Launch Affordable Alternatives to Ozempic and Wegovy
Indian drugmakers are launching cheaper versions of Ozempic and Wegovy, enhancing treatment accessibility for diabetes and obesity management.
Torrent Pharma Launches India’s First Oral Semaglutide for Weight Loss
Torrent Pharma has launched India’s first oral semaglutide, alongside an injectable option priced at ₹3,999/month, revolutionizing obesity treatment.
Torrent Pharma Launches India’s First Oral Semaglutide at ₹3,999/Month
Torrent Pharma has launched India’s first oral semaglutide, revolutionizing diabetes management with a convenient, affordable option.
Pharmaceutical Stocks Surge as Ozempic Ingredient Patent Expires
Pharmaceutical stocks have surged up to 4% as Ozempic’s key ingredient patent expires, paving the way for generics and transforming obesity treatment.
Natco Introduces Semaglutide at Rs 1,290: A New Era for Diabetes Treatment
Natco Pharma launches semaglutide at Rs 1,290, aiming to make diabetes treatment more accessible and reshape the weight-loss drug market in India.
Semaglutide Patent Expiration Sparks Weight Loss Industry Boom
The expiration of semaglutide’s patent signals a transformative era for weight loss treatments, with generics likely to enhance accessibility.